Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis.

[1]  G. Guyatt,et al.  Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. , 2008, Archives of internal medicine.

[2]  G. Guyatt,et al.  Systematic reviewers neglect bias that results from trials stopped early for benefit. , 2007, Journal of clinical epidemiology.

[3]  D. Cook,et al.  Bleeding during critical illness: a prospective cohort study using a new measurement tool. , 2007, Clinical and investigative medicine. Medecine clinique et experimentale.

[4]  L. Burgio,et al.  Data and safety monitoring in social behavioral intervention trials: the REACH II experience , 2006, Clinical trials.

[5]  M. Meade,et al.  Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. , 2005, Journal of critical care.

[6]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[7]  G. Guyatt,et al.  Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors , 2005, Critical care medicine.

[8]  Sydes,et al.  A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.

[9]  D. Cook,et al.  The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations. , 2004, American journal of respiratory and critical care medicine.

[10]  D. Cook,et al.  Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. , 2004, Journal of the American Society of Nephrology : JASN.

[11]  L. Wilhelmsen.  Role of the Data and Safety Monitoring Committee (DSMC) , 2002, Statistics in medicine.

[12]  David L. DeMets,et al.  Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .

[13]  R. Califf,et al.  Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. , 2002, American heart journal.

[14]  Core Safeguards for Clinical Research with Adults Who Are Unable To Consent , 2001, Annals of Internal Medicine.

[15]  G. Guyatt,et al.  Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. , 1998, Journal of critical care.

[16]  D. Ingram,et al.  Statistics in Practice , 1983 .